Elanco Animal Health INC Form 4 insider transactions

NYSE
Elanco Animal Health EVP and CFO, Robert M. VanHimbergen, reported a transaction involving deferred stock units on May 29, 2026.
NYSE
Rajeev A. Modi of Elanco Animal Health reports a transaction involving deferred stock units, settling 61,9258 units on May 29, 2026.
NYSE
Jeffrey N. Simmons, CEO of Elanco Animal Health, reported a transaction involving deferred stock units on May 29, 2026.
NYSE
Denise Scots-Knight, a Director at Elanco Animal Health Inc., reported the acquisition of deferred stock units and restricted stock units on May 21, 2026.
NYSE
Lawrence Kurzius, a Director at Elanco Animal Health Inc., received deferred stock units and restricted stock units on May 21, 2026, as part of annual equity awards.
NYSE
Kirk P. McDonald, a Director at Elanco Animal Health Inc., received deferred stock units and restricted stock units as part of annual equity awards.
NYSE
Elanco Animal Health Inc. reports on equity awards granted to its non-employee directors, including deferred stock units and restricted stock units.
NYSE
Deborah Turner Kochevar, a Director at Elanco Animal Health Inc., was granted deferred stock units as part of an annual equity award.
NYSE
R. David Hoover, a Director at Elanco Animal Health Inc., received a grant of deferred stock units as part of an annual equity award.
NYSE
Michael J. Harrington, a Director at Elanco Animal Health Inc., received deferred stock units and restricted stock units as part of annual equity awards.
NYSE
Elanco Animal Health Inc. reports that Director Anand Kapila acquired shares through grants of deferred and restricted stock units.
NYSE
Stacey Ma, a Director at Elanco Animal Health Inc., has reported the acquisition of deferred stock units and restricted stock units.
NYSE
Director Art A. Garcia of Elanco Animal Health Inc. acquired shares through equity awards, increasing his beneficial ownership.
NYSE
Rajeev A. Modi, Executive Vice President at Elanco Animal Health, acquired company shares and deferred stock units on May 15, 2026.
NYSE
Jeffrey N. Simmons, President, CEO, and Director of Elanco Animal Health Inc., reported a transaction involving the acquisition of common stock.
NYSE
Rajeev A. Modi, Executive Vice President at Elanco Animal Health, reported a transaction involving deferred stock units.
NYSE
Elanco Animal Health Inc. reports a transaction involving deferred stock units by President, CEO, and Director Jeffrey N. Simmons.
NYSE
Elanco Animal Health CEO Jeffrey N. Simmons acquired 119.3805 deferred stock units as part of the company's executive compensation plan.
NYSE
Elanco Animal Health CFO Robert M. VanHimbergen acquired 8.3201 deferred stock units as part of a company compensation plan.
NYSE
Elanco Animal Health executive Rajeev A. Modi acquired 62.3704 deferred stock units as part of a company compensation plan.
NYSE
Rajeev A. Modi, Executive Vice President at Elanco Animal Health Inc., acquired deferred stock units representing the right to receive company common stock.
NYSE
Jeffrey N. Simmons, President, CEO, and Director of Elanco Animal Health Inc., reported a transaction involving deferred stock units.
NYSE
Robert M. VanHimbergen, EVP and CFO of Elanco Animal Health Inc., acquired deferred stock units representing the right to receive company common stock.
NYSE
Ellen de Brabander, Executive Vice President at Elanco Animal Health, reported transactions involving company common stock.
NYSE
Director Kapila K. Anand acquired 600.7104 deferred stock units in Elanco Animal Health through a director fee deferral plan.
NYSE
Elanco Animal Health Inc.'s President and CEO, Jeffrey N. Simmons, acquired 117.887 deferred stock units.
NYSE
Elanco Animal Health Inc. Executive Vice President Rajeev A. Modi acquired 61.5901 deferred stock units, increasing his beneficial ownership to 9,072.9178 units.
NYSE
Elanco Animal Health Inc.'s EVP and CFO, Robert M. VanHimbergen, acquired 8.216 deferred stock units under a pre-arranged plan.
NYSE
Elanco Animal Health's Executive Vice President, Rajeev A. Modi, disposed of 4,392 shares of common stock to cover tax withholding obligations.
NYSE
Elanco Animal Health Inc.'s General Counsel and Corporate Secretary, Shiv O'Neill, reported a disposition of 4,738 common shares at $24.88 each, primarily for tax liability.